Lately I've seen some biotechs like Marina Biotech, Benitec and Arrowhead Research stay above their capital raise prices and continue to move higher with no movement toward the capital raise share price. This hungry environment for development biotechs has changed the old rules where a capital raise would bring the price down to that level. Especially since these results don't incorporate the new class I Mayo antigen.
I tend to agree - in addition - we were in the mid to low 2's for several weeks pre-split - some folks had the opportunity to flip this for a 100% or close to 100% gain in a very short time - so there is going to be some price pressure despite the news- I personally think mid-$4's is stellar to hold - I am very happy with the price action lately and 25K shares of total vol is nothing - once we get the volume we deserve (as you alluded to ) we will step higher and higher.
Smart money is taking a close look at this news and buying on any weakness. JMHO.
News 
Market Data 
Discover 
